Curcumin's role in preventing atherosclerotic plaque formation, platelet aggregation, and LDL oxidation indicates multiple cardiovascular benefits, and its ability to inhibit angiogenesis and induce cancer cell apoptosis suggests both preventative and therapeutic benefits. Prospective clinical trial data have also shown Theracurmin to be effective in relieving symptoms of knee osteoarthritis and reducing the need for rescue medications.
The limiting factor in curcumin's effectiveness is its low systemic bioavailability, as it is poorly absorbed in the gastrointestinal tract and rapidly metabolized. The advanced manufacturing techniques used to make Theracurmin have reduced its particle size by more than 100 times, and the combined use of natural substances such as emulsifiers to form a colloidal suspension have significantly increased the bioavailability of curcumin. This significantly increases blood levels of curcumin, many times higher than other preparations, including so-called enhanced forms of curcumin. Theracurmin increases curcumin levels in a linear, dose-dependent manner, circumventing previous limitations of curcumin supplementation to achieve unprecedented blood levels of curcumin. Detailed absorption studies have proven Theracurmin to be the best-absorbed form of curcumin on the market.
A scientific review found that Theracurmin was more bioavailable, milligram for milligram, than other enhanced and regular forms of curcumin.